Novo Nordisk’s Sogroya moves closer to becoming EU’s first approved treatment for idiopathic short stature
European regulators have backed once-weekly Sogroya for children with idiopathic short stature, potentially giving Novo Nordisk the first EU-approved growth hormone specifically for the condition while expanding a rare-endocrine franchise beyond growth hormone deficiency.